Erik C Dreaden, PhD
Prior to joining Georgia Tech and Emory School of Medicine in 2017, Dr. Dreaden completed his postdoctoral training at the Koch Institute for Integrative Cancer Research at MIT, where his work sought to apply polymer engineering to improve the therapeutic potential of nucleic acid and rational combination and cancer therapies. His PhD training at Georgia Tech was likewise application-directed, focusing on the development of multivalent and photo-activated targeted cancer therapies based on nanoscale colloids. He is a native Atlantan and a life-long Braves fan.
Dr. Dreaden’s research seeks to utilize molecular and nanoscale engineering as a means to impart augmented, amplified, or non-natural function to tumor therapies and immunotherapies. The overall goal of his research is to engineer molecular and nanoscale tools that can (i) improve our understanding of fundamental tumor biology and (ii) simultaneously serve as cancer therapies that are more tissue-exclusive and patient-personalized. The lab currently focuses on three main application areas: optically-triggered immunotherapies, combination therapies for pediatric cancers, and nanoscale cancer vaccines. His work aims to translate these technologies into the clinic and beyond.
- Kirschstein Postdoctoral Fellow – Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- PhD – Chemistry & Biochemistry, Georgia Institute of Technology
- BS – Chemistry, University of Georgia